News

Hosted on MSN11m
Sarepta Therapeutics laying off dozens in Ohio, won't comply with FDA request to halt therapy
On an investor call on Friday, analysts asked Sarepta why it had not disclosed the latest patient death on Wednesday, when it announced 500 layoffs and cuts to its limb-girdle muscular dystrophy ...
STAT1hOpinion
The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear
The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...
Sarepta shares cut to $0 at H.C. Wainwright
H.C. Wainwright sets a rare $0 target for Sarepta Therapeutics amid FDA scrutiny over its Duchenne muscular dystrophy gene therapy Elevidys. Read more here.
Nonprofit says federal proposal would gut key programs for Ohioans with disabilities
A nonprofit in Ohio is navigating uncertainty with several programs on the chopping block. Disability Rights Ohio serves as an advocate for people with disabilities.
Biogen invests $2B in U.S. manufacturing — but not in Massachusetts
Biogen is investing $2 billion in its U.S. manufacturing footprint — but not in Massachusetts, where the drug company is ...
STAT3hOpinion
We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress
As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...
Cambridge pharma company lays off almost 500 amid FDA dispute over treatment
A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.
GSK to lay off 150 Cambridge employees
British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...
Stocktwits on MSN17h
GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why
Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF ...